Jazz Pharmaceuticals (JAZZ) Accounts Payables (2010 - 2026)

Jazz Pharmaceuticals has reported Accounts Payables for 17 years, with the latest figure at $100.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 4.24% year-over-year to $100.0 million; the trailing twelve-month figure through Mar 2026 stood at $100.0 million (up 4.24% YoY), and the FY2025 full-year result was $122.1 million, up 56.8% from the prior year.
• Accounts Payables for Q1 2026 stood at $100.0 million, down from $122.1 million in the prior quarter.
• The five-year high for Accounts Payables was $152.2 million in Q3 2025, with the low at $73.3 million in Q1 2022.
• Average Accounts Payables over 5 years is $98.7 million, with a median of $97.1 million recorded in 2024.
• Year-over-year, Accounts Payables plunged 35.45% in 2024 and jumped 78.2% in 2025.
• Tracing JAZZ's Accounts Payables over 5 years: stood at $90.8 million in 2022, then gained by 13.21% to $102.8 million in 2023, then decreased by 24.22% to $77.9 million in 2024, then jumped by 56.8% to $122.1 million in 2025, then fell by 18.1% to $100.0 million in 2026.
• The last three Accounts Payables figures came in at $100.0 million (Q1 2026), $122.1 million (Q4 2025), and $152.2 million (Q3 2025), per Business Quant data.

Peer Comparison